Download App

Log in to access Online Inquiry
Company Overview More
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
CEO: Greenleaf M.B.A., Peter S.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

AUPH Aurinia Pharmaceuticals

11.450+0.090+0.79%
Close 05/26 20:00 ET
11.560+0.11+0.96%
Pre Mkt Price 05/27 08:20 ET
High
11.790
Open
11.340
Turnover
10.71M
Low
11.300
Pre Close
11.360
Volume
925.17K
Market Cap
1.62B
P/E(TTM)
Loss
52wk High
33.972
Shares
141.74M
P/E(Static)
Loss
52wk Low
8.860
Float Cap
1.57B
Bid/Ask %
73.33%
Historical High
33.972
Shs Float
136.92M
Volume Ratio
0.57
Historical Low
1.000
Dividend TTM
--
Div Yield TTM
450
P/B
3.62
Dividend LFY
--
Div Yield LFY
3930.13%
Turnover Ratio
0.68%
Amplitude
4.31%
Avg Price
11.573
Lot Size
1
Float Cap
1.57B
Bid/Ask %
73.33%
Historical High
33.972
Shs Float
136.92M
Volume Ratio
0.57
Historical Low
1.000
Dividend TTM
--
P/B
3.62
Dividend LFY
--
Turnover Ratio
0.68%
Amplitude
4.31%
Avg Price
11.573
Lot Size
1
Price Forecast

No Data

News

Comment